7/1/02

Form 6-K



SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of . . . . . July 2002

.....Teva Pharmaceutical Industries Limited.....
(Translation of registrant's name into English)

.....5 Basel Street, P.O. Box 3190.....
.....Petach Tikva 49131, Israel.....
(Address of principal executive offices)

CR 8/1

Teva Pharmaceutical Industries Ltd. Web Site www.tevapharm.com

Contact: Dan Suesskind
Chief Financial Officer
Teva Pharmaceutical Industries Ltd.
(011) 972-2-589-2840

Bill Fletcher
President and CEO
Teva North America
(215) 591-8800

Dorit Meltzer
Director, Investor Relations
Teva Pharmaceutical Industries Ltd.
(011) 972-3-926-7554

FOR IMMEDIATE RELEASE

TEVA CLOSES ACQUISITION OF BAYER'S FRENCH GENERIC OPERATIONS

Jerusalem, Israel, July 1, 2002 – Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced today, that further to its announcement dated April 4, 2002, it has completed its acquisition, for cash, of the French generic operations of Bayer Pharma S.A. - Bayer Classics S.A. and a production site located in Sens.

Bayer Classics, the third largest supplier of generic pharmaceuticals to the French retail market, will be named Teva Classics. Teva, through the combination of its existing operations in France and the new operations, will offer the French market 72 generic products (in 153 presentations) and will have 49 products in the pipeline of pending generic product registrations.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients.

Safe Harbor Statement *under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on a strategy of acquiring companies and on strategic alliances, exposure to product liability claims, dependence on patent and other protections for our innovative products, fluctuations in currency, exchange and interest rates, operating results, and other factors that are discussed in the Company's Annual Report on Form 20-F and the Company's other filings with the U. S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.*

Teva Pharmaceutical Industries Ltd. Web Site: www.tevapharm.com

Contacts: Dan Suesskind
Chief Financial Officer
Teva Pharmaceutical Industries Ltd.
(011) 972-2-589-2840

Bill Fletcher
President and CEO
Teva Pharmaceuticals North America
(215) 591-8800

FOR IMMEDIATE RELEASE

Dorit Meltzer
Director, Investor Relations
Teva Pharmaceutical Industries Ltd.
(011) 972-3-926-7554

TEVA ANNOUNCES APPROVAL OF LISINOPRIL TABLETS AND LISINOPRIL HCTZ TABLETS

Jerusalem, Israel, July 1, 2002 – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has issued final approval for the company's ANDA for Lisinopril Tablets USP, 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg as well as its ANDA for Lisinopril and Hydrochlorothiazide Tablets, 10 mg/12.5 mg, 20 mg/12.5 mg and 20 mg/25 mg. Both products will be shipped immediately.

Lisinopril Tablets are the AB-rated generic equivalent of AstraZeneca's Zestril® Tablets for the treatment of hypertension, acute myocardial infarction, and as adjunctive therapy in the treatment of heart failure.
Lisinopril and Hydrochlorothiazide Tablets are the AB-rated generic equivalent of Merck's' Prinzide® Tablets and are indicated for the treatment of hypertension.

The annual sales for the combined branded markets of Lisinopril and Lisinopril HCTZ is approximately $1.64 billion.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

Teva Pharmaceutical
Industries Limited
.....
(Registrant)

By: Dan S. Suesskind
Dan Suesskind
Chief Financial Officer

Date: ...JULY 2,..2002.....